OmniGuide Holdings and UROTECH announce a strategic partnership to enhance urological therapy

OmniGuide Holdings (OGH) and UROTECH®, a Medi-Globe Group entity and subsidiary of DCC plc, have recently revealed their new collaboration aimed at enriching UROTECH's technological portfolio for urologists. This partnership aims to establish a global network around RevoLix™ HTL (Hybrid Thulium Laser Therapy), targeting the treatment of kidney stones and benign prostatic hyperplasia (BPH).

As a major manufacturer in the field of minimally invasive urology, UROTECH places kidney stone treatment at the core of its mission, committing to superior product quality and clinical experience. OmniGuide, known for its advanced solutions in urological surgical therapies, will bring its expertise in robotics, precision light therapies, and biosensitivity software.

The goal of this international collaboration is to support future surgical trends by providing valuable data for urological decisions. Both companies aim to accelerate these efforts to achieve their common goal and enhance overall surgical expertise. Among the supported projects, expanding global capacity for kidney stone and BPH treatments through RevoLix™ HTL will be prioritized, as well as the development of a biosensitivity software platform.